Altimmune, Inc. (ALT) Stock

Altimmune, Inc. (ALT) is a Healthcare stock trading at $3.10 (as of 2026-08-21), with a market capitalization of $602.87M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Understand Altimmune, Inc.: how it makes money

Altimmune, Inc. develops clinical-stage drug candidates for obesity and liver diseases, including pemvidutide (a GLP-1/glucagon dual receptor agonist) and HepTcell (an immunotherapeutic), advancing them through Phase 1b and Phase 2 clinical trials.

Altimmune’s value hinges on clinical progress, specifically whether its lead candidates (pemvidutide in obesity and non-alcoholic steatohepatitis, and HepTcell in hepatitis B) generate credible trial efficacy signals and advance through ongoing trial milestones toward regulatory-grade outcomes.

Business quality (Weak): Two active clinical programs with measurable early trial signals, but results are still early stage (Phase 1b and Phase 2), so development risk remains high.

Bull case

Lead obesity program shows early efficacy signals: Pemvidutide has an Absolute Mean Weight Loss at 12 Weeks for the 1.8 Milligram Dose Arm of 10.3 percent, alongside other lipid and liver-related measures reported in the provided operating metrics.
Good execution visibility on Phase 1b enrollment: The Enrollment Completion Percentage for the Phase 1b Nonalcoholic Fatty Liver Disease Trial is 90.0 percent, indicating the trial is largely completed from an enrollment standpoint.
Second program targets a distinct liver disease mechanism: Altimmune is also developing HepTcell, an immunotherapeutic in a Phase 2 trial for chronically infected hepatitis B patients.

Bear case

Still early stage, with uncertain path to approval: Pemvidutide is in Phase 1b and HepTcell is in Phase 2, so the company has not yet demonstrated late-stage or regulatory-grade results based on the provided facts.
Some liver-fat findings are explicitly exploratory: The Relative Liver Fat Reduction at 12 Weeks for the 1.8 Milligram Dose Group is reported as an exploratory subset result, which can increase uncertainty versus primary endpoints.
Operational performance is not reflected in revenue yet: In the latest reported quarter (2026-03-31), revenue is 0.0B, and the operating margin is -835.7, which highlights ongoing losses rather than commercial scale.

Valuation — source: SEC EDGAR (first-party)
Price	$3.10
Market Cap	$602.87M
Price / Book	1.27
Price / Sales	58.34
FCF Yield	-22.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$41000.00
Net Margin	-214861.0%
Revenue Growth (YoY)	105.0%
EPS Growth (YoY)	-25.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.16 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($39.41M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jerome Benedict Durso
Employees	59
Country	US
IPO Date	2017-05-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.